ARBUTUS BIOPHARMA CORP (ABUS) Stock News
NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD
ABUS Latest News, Press Relases and Analysis
Arbutus Provides 2025 Corporate and Financial Update
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and...
Arbutus Provides 2025 Corporate and Financial Update
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage...
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial ...
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Mentions: BRNS
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage...
Arbutus to Present at Jefferies London Healthcare Conference
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending...
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage...
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage...
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible future actions.
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage...
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...
Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology firm Arbutus (NASDAQ:ABUS) — which specializes in virology ...
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV...
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE...
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Mentions: BRNS
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy...
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
Arbutus to Participate in Jefferies Global Healthcare Conference
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its...
Arbutus to Participate in Jefferies Global Healthcare Conference
Arbutus to Present Imdusiran Data at EASL Congress 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...